The biotech firm priced 18.17M shares and 1.83M pre-funded warrants, expanding its public offering to $600M.
Tango Therapeutics priced an upsized public offering, raising approximately $600M through the sale of 18.17M common shares and pre-funded warrants for 1.83M shares at $30 per share. The move reflects strong investor demand for the biotech firm’s capital raise.
The offering was expanded from its initial size, signaling confidence in Tango’s pipeline and financial strategy. Proceeds are expected to support ongoing research and development initiatives, though specific allocations were not disclosed.
Shares of Tango Therapeutics were last active in after-hours trading, though no immediate market reaction was detailed in the announcement.